This study, called CHAAMP, is looking for people at higher risk for a blood cancer called multiple myeloma. The goal is to find multiple myeloma early, when it's still in a pre-cancerous stage called MGUS (Monoclonal Gammopathy of Undetermined Significance). By finding it early, doctors hope to prevent delays in diagnosis, reduce health problems from the cancer, and improve long-term health. You might be able to join if you are 30 or older and identify as Black and/or African American, OR if you have a close relative (parent, sibling, or child) with a plasma cell disorder like MGUS or multiple myeloma. The study involves a blood draw to check for MGUS. The main goal is to see how many people enroll in the study over one year. This is a pilot study, meaning it's testing the study methods before a larger effort begins.

Study design

This is an observational study, meaning researchers will observe participants without giving them a specific treatment. The study plans to enroll 1665 participants.

What's involved

You would have a screening blood sample collected. If you screen positive for monoclonal gammopathy, you would be referred to a clinic for further evaluation. If diagnosed with MGUS or smoldering multiple myeloma, you would be followed for 10 years.

Compensation

Not stated in the trial record.

Follow-up

Participants diagnosed with MGUS and smoldering multiple myeloma will be followed for 10 years. Participants with other plasma cell disorders will be followed for overall survival only.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.